Video
SynBio + Pharma: Revolutionizing the Future of Medicine Main Stage at SynBioBeta 2023
The panel discussion at last year's SynBioBeta 2023 Main Stage focused on the revolutionary potential of synthetic biology in biopharma and the future of medicine. Moderated by Meenakshi Prabhune, Editor-in-Chief at The Scientist, the panelists discussed the advancements, challenges, and future directions of synthetic biology in the biopharma industry.
The panel discussion at last year's SynBioBeta 2023 Main Stage focused on the revolutionary potential of synthetic biology in biopharma and the future of medicine. Moderated by Meenakshi Prabhune, Editor-in-Chief at The Scientist, the panelists discussed the advancements, challenges, and future directions of synthetic biology in the biopharma industry.
Moderated by Meenakshi Prabhune, Editor-in-Chief at The Scientist, the panelists discussed the advancements, challenges, and future directions of synthetic biology in the biopharma industry.
The panelists included Kaan Certel, Sanofi, Jason Kelly, Ginkgo, Mark Kotter, bit.bio, Lesley Stolz, Johnson & Johnson and Ron Weiss, Professor at MIT.
They began by acknowledging the significant growth of synthetic biology in recent years and its potential to transform medicine. Ron Weiss highlighted the evolution of synthetic biology from its early days of basic research to its current applications in mammalian synthetic biology, particularly in the areas of cell-based and gene therapies.
Mark Kotter emphasised the importance of collaboration and leveraging synthetic biology's deep tech stack across various domains of biology to tackle significant medical challenges. Jason Kelly shared the need for a shift in mindset towards embracing biopharma in the synthetic biology community and highlighted the role of platforms like Ginkgo Bioworks in providing infrastructure and support for synthetic biology applications.
The panelists discussed challenges such as delivery to target cells, regulatory hurdles, and the need for innovative business models in the current funding environment. They also highlighted the importance of engaging with regulatory agencies to facilitate faster iterations and approvals for synthetic biology-based therapies.
Overall, the panel underscored the importance of collaboration, innovation, and regulatory engagement in harnessing the full potential of synthetic biology to revolutionise biopharma and address unmet medical needs.
The panelists included Kaan Certel, Sanofi, Jason Kelly, Ginkgo, Mark Kotter, bit.bio, Lesley Stolz, Johnson & Johnson and Ron Weiss, Professor at MIT.
They began by acknowledging the significant growth of synthetic biology in recent years and its potential to transform medicine. Ron Weiss highlighted the evolution of synthetic biology from its early days of basic research to its current applications in mammalian synthetic biology, particularly in the areas of cell-based and gene therapies.
Mark Kotter emphasised the importance of collaboration and leveraging synthetic biology's deep tech stack across various domains of biology to tackle significant medical challenges. Jason Kelly shared the need for a shift in mindset towards embracing biopharma in the synthetic biology community and highlighted the role of platforms like Ginkgo Bioworks in providing infrastructure and support for synthetic biology applications.
The panelists discussed challenges such as delivery to target cells, regulatory hurdles, and the need for innovative business models in the current funding environment. They also highlighted the importance of engaging with regulatory agencies to facilitate faster iterations and approvals for synthetic biology-based therapies.
Overall, the panel underscored the importance of collaboration, innovation, and regulatory engagement in harnessing the full potential of synthetic biology to revolutionise biopharma and address unmet medical needs.